Ironwood Pharmaceuticals, Inc. (IRWD)
4.125
-0.16
(-3.85%)
USD |
NASDAQ |
Aug 24, 16:00
4.14
+0.02
(+0.36%)
After-Hours: 20:00
Ironwood Pharmaceuticals Net Income (Quarterly) : 51.29M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 51.29M |
| March 31, 2026 | 40.77M |
| December 31, 2025 | -2.276M |
| September 30, 2025 | 40.08M |
| June 30, 2025 | 23.60M |
| March 31, 2025 | -37.39M |
| December 31, 2024 | 2.256M |
| September 30, 2024 | 3.646M |
| June 30, 2024 | -0.86M |
| March 31, 2024 | -4.162M |
| December 31, 2023 | -1.745M |
| September 30, 2023 | 13.95M |
| June 30, 2023 | -1.089B |
| March 31, 2023 | 45.71M |
| December 31, 2022 | 48.87M |
| September 30, 2022 | 50.32M |
| June 30, 2022 | 37.08M |
| March 31, 2022 | 38.80M |
| December 31, 2021 | 41.37M |
| September 30, 2021 | 55.84M |
| June 30, 2021 | 391.30M |
| March 31, 2021 | 39.93M |
| December 31, 2020 | 43.20M |
| September 30, 2020 | 34.42M |
| June 30, 2020 | 25.20M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.345M |
| December 31, 2019 | 47.86M |
| September 30, 2019 | 20.65M |
| June 30, 2019 | 12.28M |
| March 31, 2019 | -21.85M |
| December 31, 2018 | 8.373M |
| September 30, 2018 | -151.82M |
| June 30, 2018 | -24.14M |
| March 31, 2018 | -43.14M |
| December 31, 2017 | 12.08M |
| September 30, 2017 | -32.30M |
| June 30, 2017 | -44.22M |
| March 31, 2017 | -52.50M |
| December 31, 2016 | -13.50M |
| September 30, 2016 | -33.20M |
| June 30, 2016 | -21.70M |
| March 31, 2016 | -13.30M |
| December 31, 2015 | -14.04M |
| September 30, 2015 | -47.39M |
| June 30, 2015 | -48.02M |
| March 31, 2015 | -33.22M |
| December 31, 2014 | -37.65M |
| September 30, 2014 | -41.99M |
| June 30, 2014 | -60.36M |
| March 31, 2014 | -49.63M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| Rigel Pharmaceuticals, Inc. | 17.29M |
| Marker Therapeutics, Inc. | -1.826M |
| Verastem, Inc. | -34.67M |
| Theriva Biologics, Inc. | -3.217M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 113.04M |
| Total Expenses (Quarterly) | 61.75M |
| EPS Diluted (Quarterly) | 0.3068 |
| Enterprise Value | 1.027B |
| Gross Profit Margin (Quarterly) | 99.60% |
| Profit Margin (Quarterly) | 45.37% |
| Earnings Yield | 18.59% |
| Operating Earnings Yield | 33.96% |
| Normalized Earnings Yield | 18.77 |